Gender differences in the associations of multiple psychiatric and chronic conditions with major depressive disorder among patients with opioid use disorder

Nwabueze, Christian; Elom, Hilary; Liu, Sophia; Walter, Suzy Mascaro; Sha, Zhanxin; Acevedo, Priscila; Liu, Ying; Su, Brenda Bin; Chun, Xu; Piamjariyakul, Ubolrat; Wang, Kesheng

doi:10.1080/10550887.2021.1957639

Cited by 3 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over 50% of women with SUD issues have experienced physical and/or sexual abuse and, as a result, many also suffer post-traumatic stress disorder (Bailey et al, 2019). In fact, women with SUD are more likely to suffer multiple comorbidities, and those with mental health disorders more often have a history of trauma when compared to men (Brady and Lydiard, 2021; Nwabueze et al, 2021). Indeed, Serdarevic et al (2019) found that, amongst older women, concurrent hazardous alcohol and opioid use was significantly associated with depression and anxiety, highlighting the need to tailor interventions accordingly (Serdarevic et al, 2019).…”

Section: Experience Of Trauma Mental Health Comorbidities and Related...mentioning

confidence: 99%

Examining the gender dimension in the non-medical use of over the counter and prescription only medication

Gittins

Teck

Madill

2022

Drug Science, Policy and Law

View full text Add to dashboard Cite

There is concern regarding gender differences in problematic non-medical over the counter (OTC) and/or prescription only medication (POM) use. This issue has traditionally been considered a predominantly male and/or younger persons’ problem, but more recent transnational evidence shows that women across their life-course are increasingly and often more severely affected. Nevertheless, the bulk of research, policy and treatment services continue to be focused on men. This suggests the need for increased awareness, a shift in research and policy agenda and improved treatment access and engagement approaches, informed by a robust examination of the gender dimension. We present here a summary of current evidence around the epidemiology of non-medical use of OTC and POM and highlight the gender differences across the domains of healthcare interactions, changes across the life-course, experiences of trauma and barriers to obtaining support. We conclude by proposing a re-gendering agenda to challenge the ‘male by default’ tendency when designing, delivering and evaluating treatment services. For example, utilising co-production with a strengths-based approach has been found to balance gender power with positive outcomes for participants. Such approaches can help to address stigma and marginalisation, by embedding the lived experiences and voices of women in designing and providing treatment services, safe spaces and gender-sensitive treatment programs. It also means promoting coordinated, holistic, multidisciplinary and multi-agency approaches, and establishing a research strategy to fill knowledge gaps around the experiences of women. These changes should improve engagement with treatment services and consequent outcomes, especially in relation to OTC/POM.

show abstract

Section: Experience Of Trauma Mental Health Comorbidities and Related...mentioning

confidence: 99%

Examining the gender dimension in the non-medical use of over the counter and prescription only medication

Gittins

Teck

Madill

2022

Drug Science, Policy and Law

View full text Add to dashboard Cite

show abstract

Repeated measures analysis of opioid use disorder treatment on clinical opiate withdrawal scale in a randomized clinical trial: sex differences

Wang

Shafique

Xiao

et al. 2023

Journal of Addictive Diseases

View full text Add to dashboard Cite

Effect of Neonatal Abstinence Syndrome Treatment Status and Maternal Depressive Symptomatology on Maternal Reports of Infant Behaviors

Heller

Logan

Shrestha

et al. 2023

Journal of Pediatric Psychology

View full text Add to dashboard Cite

Objective The objective of this study is to investigate the effects of maternal perinatal depression symptoms and infant treatment status for neonatal abstinence syndrome (NAS) on maternal perceptions of infant regulatory behavior at 6 weeks of age. Methods Mothers and their infants (N = 106; 53 dyads) were recruited from a rural, White cohort in Northeast Maine. Mothers in medication-assisted treatment (methadone) and their infants (n = 35 dyads) were divided based on the infant’s NAS pharmacological treatment (n = 20, NAS+ group; n = 15, NAS− group) and compared with a demographically similar, nonexposed comparison group (n = 18 dyads; COMP group). At 6 weeks postpartum, mothers reported their depression symptoms Beck Depression Inventory—2nd Edition) and infant regulatory behaviors [Mother and Baby Scales (MABS)]. Infant neurobehavior was assessed during the same visit using the Neonatal Network Neurobehavioral Scale (NNNS). Results Mothers in the NAS+ group showed significantly higher depression scores than the COMP group (p < .05) while the NAS− group did not. Across the sample, mothers with higher depression scores reported higher infant “unsettled-irregularity” MABS scores, regardless of group status. Agreement between maternal reports of infant regulatory behaviors and observer-assessed NNNS summary scares was poor in both the NAS+ and COMP groups. Conclusions Postpartum women in opioid recovery with infants requiring pharmacological intervention for NAS are more at risk for depression which may adversely influence their perceptions of their infants’ regulatory profiles. Unique, targeted attachment interventions may be needed for this population.

show abstract

Gender differences in the associations of multiple psychiatric and chronic conditions with major depressive disorder among patients with opioid use disorder

Cited by 3 publications

References 57 publications

Examining the gender dimension in the non-medical use of over the counter and prescription only medication

Examining the gender dimension in the non-medical use of over the counter and prescription only medication

Repeated measures analysis of opioid use disorder treatment on clinical opiate withdrawal scale in a randomized clinical trial: sex differences

Effect of Neonatal Abstinence Syndrome Treatment Status and Maternal Depressive Symptomatology on Maternal Reports of Infant Behaviors

Contact Info

Product

Resources

About